EU approves Jascayd as first new IPF oral treatment in a decade

The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing authorization from the European Commission follows a positive recommendation from a regulatory committee and marks the first new IPF therapy approved in the EU in more than a decade, […] The post EU approves…